24/03/2022 09:19

Fisher & Paykel Corp Ltd (FPH) $23.73

Medical device company FPH was the market’s worst performer yesterday falling almost 8% after management outlined how its business had been impacted by the Omicron variant plus heavy freight costs – an estimated drop in full-year revenue of up to 15% rarely goes down well. The stock was in vogue during the outbreak of the coronavirus due to its respiratory care products but its not delivered the lift in profits many expected, we see value in the stock back towards $20, where it was pre-COVID.

Read more

31/08/2021 09:38

Fisher & Paykal (FPH) $31.32

Respiratory company FPH has soared over recent years with the COVID outbreak providing a healthy tailwind for the company. We believe this is a strong $18bn business but its priced for ongoing strong growth however we feel much of this tailwind is already priced into the stock and there’s no hurry to be chasing at today’s valuation i.e. COVID is not going...

Read more